Coral Laboratories
- Market cap
- ₹ 176 Cr.
- P/E
- 9.4x
- P/B
- 0.87x
- 52-week range
- 360 – 679
- ROE
- 8%
- ROCE
- 11%
- Dividend yield
- 0.4%
- Debt / equity
- 0.02
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- BSE
About
Coral Laboratories Limited is an India-based pharmaceutical company. The Company is engaged in the business of pharmaceutical formulations. The Company is engaged in the manufacturing of generic - branded, nutraceuticals, over the counter (OTC), and herbal medicines. It offers dosage forms, which include tablets, capsules, liquid orals, injections (liquids and powder), ointment and creams, gels and lotions, and suppositories. Its product categories include nutraceutical, OTC, sterile and non-sterile. Its nutraceutical products include DAX 200, DAX 400 Drops, Zest drops, and Super Zestcal Tablets. Its OTC products include herbal range, skin care, medical devices, and effervescent range. Its sterile products include small volume liquid - injectables, lyophilized range - injectables, eye drops, and eardrops. Its non-sterile antibiotics/antibacterials, antifungals, gastro-intestinal drugs, anti-emetics, and muscle relaxants. The Company also exports its products to various countries.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Coral Laboratories against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)9.4 against a typical 34.3: cheaper than most peers (1st = cheapest).17th of 220
- Sales growth+57.4% against a typical +15.6% from a year earlier.25th of 197
- Profit growth+110.5% against a typical +18.9% from a year earlier.30th of 160
- Share price, 3 months−8.4% against a typical −0.5%.139th of 200
- Size₹ 176.5 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).122nd of 199
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 23 | 18 | 29 | 32 | 32 | 23 | 28 | 19 | 19 | 22 | 26 | 30 |
| Expenses | 17 | 16 | 23 | 21 | 26 | 17 | 25 | 17 | 14 | 20 | 20 | 24 |
| Operating Profit | 6 | 2 | 6 | 11 | 7 | 6 | 3 | 2 | 5 | 2 | 6 | 5 |
| OPM % | 26.6% | 11.6% | 21.6% | 33.9% | 20.2% | 27.5% | 9.6% | 11.6% | 26% | 8.8% | 23.4% | 18.5% |
| Other Income | 2 | 1 | 2 | 2 | 3 | 3 | 2 | 2 | 3 | 2 | 3 | 2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 |
| Profit before tax | 8 | 3 | 8 | 12 | 9 | 8 | 4 | 4 | 7 | 4 | 8 | 7 |
| Tax % | 20.2% | 27.5% | 25.2% | 25.2% | 25.2% | 26.1% | 26.5% | 31.2% | 21.6% | 24.9% | 36.9% | 22.5% |
| Net Profit | 6 | 2 | 6 | 9 | 6 | 6 | 3 | 3 | 6 | 3 | 5 | 5 |
| EPS in Rs | 16.79 | 6.05 | 16.21 | 24.63 | 17.86 | 17.19 | 7.92 | 7.17 | 16.29 | 7.78 | 14.61 | 15.09 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 1%
- 5 Years
- −2%
- 3 Years
- 3%
- TTM
- −5%
- 10 Years
- 3%
- 5 Years
- 4%
- 3 Years
- 36%
- TTM
- 3%
- 10 Years
- 4%
- 5 Years
- 10%
- 3 Years
- 38%
- TTM
- —
- 10 Years
- 9%
- 5 Years
- 8%
- 3 Years
- 10%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Coral Laboratories | ₹ 508.35 | ₹ 176 Cr. | 9.4x | 0.9x | 8% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 39.2x | 5.7x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 75x | 11.7x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 76.7x | 20.3x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.4x | 3.3x | — | 11.9% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 20.5x | 4.1x | 19.7% | 18.5% |
Management
- Sushma Shashi Kadkade
- Chief Financial Officer, Director
- Diwakar Unnikrishna Menon
- Compliance Officer, Company Secretary
- Girish M. Dhameja
- Whole Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.